Impacto de las terapias para la atrofia vulvovaginal en la calidad de vida de mujeres posmenopausicas en el estudio CRETA medida mediante la escala Cervantes.
Revista SAEGRE
pdf
html

Palabras clave

menopausia
Ospemifene

Cómo citar

1.
Orrigo C. Impacto de las terapias para la atrofia vulvovaginal en la calidad de vida de mujeres posmenopausicas en el estudio CRETA medida mediante la escala Cervantes. RSAEGRE [Internet]. 22 de julio de 2024 [citado 9 de diciembre de 2024];31(2):30-2. Disponible en: https://revistasaegre.com.ar/index.php/revista/article/view/31

Resumen

Objective: To assess the correlation of different vulvovaginal atrophy therapeutic options with the quality of life of postmenopausal women. Study design: The CRETA study is a descriptive, observational, cross-sectional, multicenter study designed to measure, besides treatment satisfaction and adherence, the quality of life of postmenopausal women diagnosed with vulvovaginal atrophy in 29 hospitals and centers across Spain. Main outcome measures: The study enrolled postmenopausal women currently receiving treatment with vaginal moisturizers, local estrogen therapy or ospemifene. Clinical features and treatment perceptions were collected by self-report questionnaire and quality of life was evaluated using the Cervantes scale. Results: Among the 752 women included, the ospemifene cohort showed a statistically significant lower global score (44.9 ± 21.7) on the Cervantes scale (and therefore, a better quality of life) than the cohorts treated with moisturizers (52.5 ± 21.6, p = 0.003) or local estrogen therapy (49.2 ± 23.8, p = 0.0473). In the analysis by domains, ospemifene-treated women showed statistically significant better scores in menopause & health and psychological status than moisturizers-treated women (p < 0.05). In the domains of sexuality and couple relations, the score for the quality of life of the ospemifene cohort was statistically significantly better than the scores in either of the cohorts treated with moisturizers (p < 0.001) or local estrogen therapy (p < 0.05). Conclusions: Postmenopausal women diagnosed with vulvovaginal atrophy and treated with ospemifene have better quality of life than women treated with vaginal moisturizers or local estrogen therapy. The improvement observed with ospemifene is more remarkable in those aspects related to sex life and couple relations.

pdf
html

Citas

S. Palacios, R.E. Nappi, N. Bruyniks, M. Particco, N. Panay, EVES Study Investigators, The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause, Climacteric 21 (3) (2018) 286–291, https://doi.org/10.1080/13697137.2018.1446930

A. Cagnacci, A. Xholl, M. Venier, Ospemifene in the management of vulvar and vaginal atrophy: focus on the assessment of patient acceptability and ease of use, Patient Prefer. Adherence 14 (2020) 55–62, https://doi.org/10.2147/ppa.s203614.

B.M. Faught, G. Soulban, J. Yeaw, et al. Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia, J. Comp. Eff. Res. 8 (13) (2019) 1111–1123, https://doi.org/10.2217/cer-2019-0091.

A. Lev-Sagie. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations, Clin. Obstet. Gynecol. 58 (3) (2015) 476–49.

S.A. Kingsberg, M. Krychman, S. Graham, B. Bernick, S. Mirkin, The Women’s EMPOWER Survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment, J. Sex. Med. 14 (3) (2017) 413–424. https://doi.org/10.1016/j.jsxm.2017.01.010.

R.E. Nappi, S. Palacios, N. Bruyniks, M. Particco, N. Panay, EVES Study Investigators, The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey, Menopause 26 (5) (2019) 485–491, https://doi.org/10.1097/GME.0000000000001260.

R.E. Nappi, S. Palacios, N. Panay, M. Particco, M.L. Krychman, Vulvar and vaginal atrophy in four European countries: evidence from the european REVIVE survey, Climacteric 19 (2) (2016) 188–197. https://doi.org/10.3109/13697137.2015.11 07039.

S. Palacios, M.J. Cancelo, C. Castelo Branco, P. Llaneza, F.

Molero, R. Sanchez ´ Borrego, Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions, Climacteric 20 (1) (2017) 55–61, https://doi.org/10.1080/13697137.2016.1262840.

Descargas

Los datos de descargas todavía no están disponibles.